Abstract A study of the assessment criteria covers the synthesis and characterization of agent and test their biological effectiveness as boron neutron capture therapy (BNCT) agents in cancer treatment. The cellular uptake of this agent into the glioblastoma cells was assessed by boron analysis (ICP-MS) and by fluorescence imaging (confocal microscopy). The agent enters the glioblastoma cells exhibiting a similar profile, i.e., preferential accumulation in the cytoskeleton and membranes and a low cytotoxic activity (IC50 values higher than 200 μM). The cytotoxic activity and cellular morphological alterations after neutron irradiation in the Research Reactor (>10 7 neutrons cm −2 s −1 ) were assessed by the MTT assay and by electron microscopy (TEM). Post neutron irradiation revealed that BNCT has a higher cytotoxic effect on the glioblastoma cells. Results provide a strong rationale for considering one of these compounds as a lead candidate for a new BNCT agent.
INTRODUCTION
Malignant gliomas are the most common type of primary malignant brain tumor and the most frequently found brain tumor diagnosed in up to 49% of cases. According to the World Health Organization (WHO) glioblastoma or grade IV glioma is the most common form of gliomas and represents one of the most aggressive and treatment resistant types of human cancer were reviewed by A. Omuro et al and M. M. Mrugala. Glioblastoma remains an incurable disease despite technological and therapeutic improvements in surgery, radiotherapy and chemotherapy or combined therapeutic modalities. The outlook has improved only modestly, and the survival rate of patients stays less than a few percent were reviewed by C. Caruso et al, and C. P. Tanase et al. The therapeutic challenge is to develop strategies that can selectively target malignant cells, with little or no effect on normal cells and tissues adjacent to the tumor. One such approach is the so-called "binary therapy" in which two non-toxic components can be combined in order to produce a cytotoxic effect. The advantage is that each component can be modulated and manipulated independently to maximize the therapeutic efficacy. A potentially useful binary system is the boron neutron capture therapy (BNCT). As a binary treatment modality, BNCT combines a radiosensitizer, 10 B (19.8 % natural abundance) with thermal neutrons (n), an indirectly ionizing radiation. The subsequent (n,α) reaction yields 1.47 MeV α particles and 0.84 MeV 7 Li ions, both having high linear energy transfer (LET) causing radiotoxic effects in the range of a cell diameter (ca. 10 μm). The efficient energy transfer produces selective damage in the cells containing 10 B so that boron content and distribution in tumor are pivotal to the therapeutic efficacy of this treatment 
MATERIAL AND EQUIPMENT
Most of the reagents used highly dependent on the compounds synthesized. All reagents were used without further purification. The internal standard was TMS. Nitrogen was used as a nebuliser gas and argon as a collision gas. Equipments used NMR and Thin Layer Chromatography. NMR spectra were recorded on Bruker Avance 300 (300.13 MHz for 1 H and 75.47 MHz for 13 C) and Bruker Avance 500 (500.13 MHz for 1 H and 125.76 MHz for 13 C) spectrometers, using CDCl3 as a solvent. Preparative thin layer chromatography was carried out with Riedel silica gel 60 DGF254 and column chromatography using Acros silica gel 60, 35-70 μm.
Synthesis
Most of the reagents used highly dependent on the compounds synthesized. As an example of the synthesized compounds can be seen in Figure 1 .
Characterization
Characterization a new BNCT agent using NMR equipment and Thin Layer Chromatography.
Cell studies
Cell culture and cellular viability. As an example human glioblastoma multiforme cell lines were cultured in DMEM with GlutaMax I (Gibco) containing 10% fetal bovine serum and 1% antibiotics under a humidified atmosphere (95% air/5% CO2) at 37°C. The cytotoxic activity of the boron compounds was determined using the MTT assay {MTT = [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]} was described E. Vega-Avila et al.
The cellular viability was evaluated by comparing the absorbance of the resulting solutions at 570 nm for the treated cells with the absorbance for non-treated cells in a multi-well plate spectrophotometer. The cytotoxic activity of the compounds was quantified by calculating the drug concentration inhibiting tumor cell growth by 50% (IC50), based on non-linear regression analysis of dose response data (GraphPad Prism software). All compounds were tested in at least two independent experiments, each comprising eight replicates per concentration.
Dosimetry
The Research Reactor was used as a neutron source for in vitro cell irradiation. Neutron irradiation was carried out at the vertical access of the thermal column of the Research Reactor, consisting of a graphite stacking that moderates the fission neutrons. Cell irradiation is performed on top of the graphite using an experimental design similar to that described by A. Irles et al and N. G. Oliveira et al. The radiation field at the irradiation facility was calculated using a general-purpose Monte Carlo code for radiation transport simulation and a detailed model which included a validated model of the reactor core was described A. C. Fernandes et al. The calculated neutron energy distribution was further adjusted via the multiple-foil activation method and standard unfolding codes. The intensity of the neutron beam varies with the distance from the core, i.e., is constant (within ± 3%) in the parallel direction and decreases with increasing distance with a larger relative contribution of thermal neutrons as more graphite is traversed. The conventional thermal neutron fluence rate (ϕ0) at the highest intensity position is > 10 7 neutrons cm −2 s −1 ; the ratio between the epithermal neutron fluence rate per unit lethargy (θ) and ϕ0 varies between 0.03% and 0.05% in the cell flask location. The contribution of epithermal neutrons to the dose received by the boron loaded cells is therefore negligible.
Regarding photon doses, low neutron sensitivity thermoluminescent dosimeters of Al2O3:Mg,Y were used to evaluate the accuracy of the photon simulations and measure the photon dose itself. It was concluded that the major (>99%) contribution to the photon dose is neutron interactions with the facility materials; therefore, a direct relation between the photon dose and the thermal neutron fluence can be derived. Details of the procedures was described Fernandes et al. The neutron fluence and photon dose received by the cells in the actual irradiation was monitored using pure gold foils underneath the cell flasks. The ratio of the foil response to the thermal and epithermal neutron fluence rates and to the photon dose rate was previously determined in a calibration run.
In vitro cell neutron irradiation
Prior to irradiation, the cells in culture flasks at a density of approximately 10 6 cells per 5 mL medium were pre-incubated for 1 h with the compounds at a concentration of 200 μM in medium. Thereafter the cells were irradiated at room temperature for 5 h.
The maximum discrepancy between the measurements and this reported value is 17% due to the neutron fluence gradient within the irradiation facility. Exponentially growing cells were distributed in the following groups: (1) untreated cells without neutrons; (2) cells + neutrons; (3) cells with the compounds at 200 μM without neutrons; and (4) cells with the compounds at 200 μM + neutrons. Cells that have not been treated with the boron compounds were used as controls. Following irradiation, the cells were placed in boron free medium under a humidified atmosphere containing 5% CO2 at 37°C. After 24 h the cellular viability was evaluated by the MTT assay. The absorbance of the resulting solutions was measured at 570 nm using a Varian DMS 80 UV-Vis spectrophotometer.
Boron analysis by ICP-MS
The total cellular boron content was analysed by Inductively Coupled Plasma Mass Spectrometer (ICP-MS). The glioblastoma cells (approx. 10 6 cells/5 mL medium) were exposed to the compounds at 200 μM for 6 h at 37°C, and then washed with ice-cold PBS and centrifuged to obtain a cellular pellet. The cytosol, membrane/particulate, cytoskeletal and nuclear fractions were extracted using a FractionPREP™ cell fractionation system (BioVision, USA) and performed according to the manufacturer's protocol. The boron content in the different fractions was measured after digestion of the samples in a closed pressurized microwave digestion unit (Mars5, CEM) with medium pressure HP500 vessels and then diluted in ultrapure water to obtain 2.0% (v/v) nitric acid. The instrument was tuned using a multielement ICP-MS 71 C standard solution (Inorganic Venture). Indium ( 115 In) at 10 mM was used as the internal standard.
Uptake by fluorescence microscopy
Cellular uptake of compounds was visualized by performing time-lapse confocal microscopy imaging of live cells.
Cells were imaged using a Zeiss LSM 510 META inverted laser scanning confocal microscope (Carl Zeiss, Germany) fitted with a large incubator at 37°C (Pecon, Germany) using a PlanApochromat 63/1.4 oilimmersion objective. Ethidium bromide fluorescence was detected using the 514 nm laser line of an argon laser (45 mW nominal output) and a 530-600 nm band-pass filter. Hoechst fluorescence was detected using a diode 405 nm laser (50 mW nominal output) and a 420-480 nm band-pass filter. The fluorescence of 4a was detected using the 420-480 nm bandpass filter. A transmission detector (PMT) was used to provide a transmission light image of the sample by detecting the scanning 488 nm laser. The pinhole aperture was adjusted in both channels to achieve the same optical slice thickness (1 μm).
Ultrastructural analysis
After irradiation (cells ± compounds + neutrons) the culture medium was replaced by a primary fixative (5 mL) consisting of glutaraldehyde (3%) in sodium cacodylate buffer (pH 7.3, 0.1 M). After primary fixation for 2 h at 4°C, the glutaraldehyde was replaced by sodium cacodylate buffer. The cells were scraped, pelleted, and embedded in agar (2%) for further processing. The samples were washed in cacodylate buffer and secondarily fixed for 3 h in osmium tetroxide (1%) in sodium cacodylate buffer (pH 7.3, 0.1 M). Then samples were washed with acetate buffer (pH 5.0, 0.1 M) and further fixed in uranyl acetate (0.5%) in the same buffer for 1 h. Dehydration was carried out with increasing concentrations of ethanol. After passage through propylene oxide, the samples were embedded in Epon-Araldite with the use of SPI-Pon as an Epon 812 substitute. Thin sections were made with glass or diamond knives and stained with aqueous uranyl acetate (2%) and Reynold's lead citrate. The stained sections were assessment and photographed with a JEOL 100-SX electron microscope.
DISCUSSION

Cytotoxicity
In order to evaluate the cytotoxicity of compound and also to select a dose for irradiation, the glioma cells, a clinically relevant tumor cell line for BNCT.
A low cytotoxicity for a boronated agent is an important parameter in BNCT so that boron concentrations within tumors can be maximised. The cytotoxic activity of the boron compounds was determined using the MTT assay which evaluates the reduction of the tetrazolium salt by a mitochondrial dehydrogenase in metabolic active cells to insoluble formazan crystals was described by E. Vega-Avila et al. The cellular viability in the presence of the tested compounds was compared to that observed in controls (no additions) and the cellular viability (%) was calculated. As an example of the corresponding inhibition curves (effect on cellular viability vs. compound concentration) compounds can be seen in Figure  2 .
In vitro BNCT
To assessment the potential of BNCT agents, their cytotoxic activities towards cells were tested after neutron irradiation for 5 h at room temperature. Compounds were added at an equimolar concentration of 200 μM. The cellular viability was determined by the MTT assay after 24 h incubation in compound free medium. The viability of cells after neutron irradiation in the presence or absence of the tested compounds was compared to that observed in controls (cells only). Neutron irradiation induced an increase in the cytotoxic effect. As an example the viability of cells can be seen in Figure. 
Cellular distribution by ICP-MS
Comparative cellular distribution studies of compound with the cells were conducted in order to determine the boron content delivered by the compound. As an example the boron content was determined by inductively-coupled plasma mass spectroscopy (ICP-MS) in cytosol, membrane/particulate, nucleus and cytoskeletal fractions isolated from cells after 6 h exposure to the compounds at 200 μM can be seen as an example in Figure. 4 This result indicates that compounds can target cellular components present mainly at the membrane or cytoskeleton, but without a cytotoxic effect, a factor that is critical in the design of new agents for BNCT. Moreover, the concentration of boron deposited into the cell is adequate for this therapeutic modality. We calculated an uptake of approx. 1.4 × 1011 B atoms and consequently 2.8 × 1010 10B atoms per cell, an amount superior to the recommended concentration of 108-109 10B atoms according to E. L. Crossley et al.
Cytotoxicity
The cellular trafficking of compounds was assessment by timelapse confocal fluorescence microscopy in live cells by taking advantage of their fluorescence properties. As an example depicted in Figure. 5, rapidly accumulates in the glioblastoma cells but not significantly in the nucleus.
CONCLUSIONS
Glioblastoma has long been the focus of BNCT research due to its radioresistance and infiltrative growth pattern. Clinical and experimental BNCT using BSH and BPA has shown potential but no proven therapeutic advantages. Research is therefore justified to further evaluate this experimental treatment modality. Recent literature reports discussed some of the more recent results and progress in BNCT, providing hope for this unique and exciting mode of clinical therapy. Two criteria must be fulfilled for clinical application of BNCT: an adequate source of high flux thermal neutrons along with a boron carrier that is able to concentrate in glioma cells and tissues. A high concentration of boron within tumor cells should be obtained in order to maximize the therapeutic effect. 
